Good Manufacturing Practice is the foundation of pharmaceutical quality assurance. It is the framework of rules, systems, and behaviors that ensures medicines are consistently produced and controlled to the quality standards appropriate to their intended use and to the requirements of their marketing authorization. In Iraq, GMP standards are adopted by the Ministry of Health and applied to all pharmaceutical manufacturing facilities whether local or foreign, supplying the Iraqi market. The regulatory expectations have been progressively raised, drawing on WHO GMP guidelines and increasingly aligning with PIC/S standards.
GMP covers every aspect of manufacturing operations: facility design, equipment qualification, personnel training, documentation, quality control testing, batch release, investigation of deviations, change management, and storage and distribution. The quality management system that ties these elements together must be documented, but more importantly it must be implemented in practice. Inspectors increasingly assess practical implementation through site walkthroughs, document review, and personnel interviews, and they are quick to recognize the difference between systems that exist only on paper and those that are genuinely operating.
Facility and Equipment
Facility and equipment qualification follows a defined lifecycle: user requirements specification, design qualification, installation qualification, operational qualification, performance qualification, and ongoing requalification under robust change control. Temperature mapping, HVAC qualification, cleaning validation, and computer system validation are all integral elements. Process validation must demonstrate that the manufacturing process consistently produces product meeting its predetermined specifications, and continued process verification ensures that this performance is maintained over time. Changes to validated processes trigger change control assessment and, where warranted, revalidation.
Quality Control
Quality control testing must be performed by qualified personnel using validated methods and following recognized pharmacopoeial standards, the US Pharmacopeia, the British Pharmacopoeia, the WHO International Pharmacopoeia, or others as applicable. Raw materials, in-process materials, and finished products must all be tested in accordance with approved specifications. Stability testing supports the assigned shelf life and informs storage conditions. Out-of-specification results must be investigated, and the laboratory itself must operate under GMP principles, including the data integrity requirements that have been a focus of regulatory attention internationally in recent years.
Documentation
Documentation underpins GMP compliance. Comprehensive records must support every aspect of operations: batch manufacturing records, batch packaging records, deviation investigations, corrective and preventive actions, change controls, complaints handling, recall procedures, and disposal of waste. Each batch produced must have a complete record documenting every step, the materials used, the equipment used, the conditions maintained, and the personnel involved. The integrity of these records, that they are complete, contemporaneous, attributable, and accurate is one of the most heavily scrutinized aspects of GMP, and lapses here are treated more seriously than lapses in many other areas.
Personnel
Personnel are central to GMP. Adequate qualifications, initial and continuing training, documented training records, and health and hygiene precautions are required. Independent reporting lines for quality assurance and quality control are important to ensure that quality functions are not subordinated to production pressures. Cultivating a quality culture across the organization is increasingly recognized as the soft side of GMP that determines whether the hard infrastructure delivers its intended results.
Ministry of Health Inspections
Ministry of Health GMP inspections are the principal mechanism by which compliance is assessed and enforced. Pre-licensing inspections occur before manufacturing authorization is granted; routine periodic inspections typically take place every two to three years; for-cause inspections may be triggered by complaints, safety concerns, or other specific events; and inspections may also be triggered by significant changes such as new dosage forms or major facility modifications. Risk-based inspection scheduling is increasingly being adopted by Iraqi regulators in line with international practice.
Inspections typically involve a combination of document review, site walkthroughs, personnel interviews, and witnessing of activities. Findings are classified as critical, major, or minor based on their severity and potential impact on product quality and patient safety. Critical observations represent significant risk to patients and must generally be resolved before manufacturing continues; major observations indicate significant departures from GMP requirements and require timely remediation; minor observations are less severe but still must be addressed within defined periods. The company’s response, corrective and preventive actions, evidence of implementation, verification by inspectors, is itself an important part of the regulatory record.
Consequences
The consequences of GMP non-compliance can be severe. Warnings and required remediation are common for less serious findings; the GMP certificate may be suspended or restricted; in serious cases revocation may follow. Suspension of GMP affects marketing authorizations for all products manufactured at the affected site, can trigger product recalls, and may give rise to civil liability for resulting patient harm. Criminal proceedings are available for the most serious cases. The cascading nature of these consequences means that GMP problems are rarely confined to the site where they originate.
Foreign Manufacturer GMP
Foreign manufacturers supplying Iraq must demonstrate GMP compliance through Iraqi authority inspection of their facilities, recognized international GMP certificates, or a combination of approaches. Foreign manufacturers must submit GMP certificates with each product registration application and periodically update them, and they must notify Iraqi authorities of significant changes including manufacturing site changes or scope expansions. The Iraqi regulator’s willingness to rely on certificates from particular foreign authorities depends on its assessment of those authorities’ inspection programs and on its experience with the manufacturers concerned.
Change Management
Manufacturing changes, site changes, active ingredient source changes, process changes, specifications changes require structured change management. Significant changes may require prior notification or approval before implementation, and the line between minor changes that can be implemented at the manufacturer’s discretion and major changes that require regulatory approval is not always intuitive. Lifecycle management of approved products is an ongoing legal obligation, and companies that fall behind on change reporting create their own future problems.
APIs
Active pharmaceutical ingredients are subject to GMP standards equivalent to those for finished pharmaceuticals. API GMP compliance is evaluated as part of finished product registration, and API GMP certificates are often required from the API manufacturer. Excipient quality, water systems used in API manufacturing, and supplier qualification are all areas of regulatory focus.
Building Sustainable Compliance
Effective GMP compliance requires more than meeting minimum requirements at the time of inspection. It requires quality culture across the organization, management commitment, investment in personnel and infrastructure, and genuine implementation of quality systems. Companies that approach GMP as a continuous discipline rather than a periodic exercise build the kind of compliance that withstands inspection and regulatory change. Those that treat it as a checklist activity tend to find that compliance erodes between inspections and that the cumulative cost of corrective action is much higher than the cost of continuous investment.
How We Can Help
Etihad Law Firm advises pharmaceutical manufacturers on GMP compliance, inspection preparation and response, regulatory enforcement actions, and product liability matters arising from manufacturing quality issues in Iraq. We provide both proactive compliance support and crisis management when significant deficiencies are identified.